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S U M M A R Y
Objectives: Ergoferon is an antiviral complex drug containing released-active forms of antibodies to
interferon gamma, CD4, and histamine. Its efﬁcacy and safety in the treatment of acute respiratory viral
infections has been reported previously. The aim of this study was to compare Ergoferon with
oseltamivir.
Methods: A multicenter, open-label, randomized controlled trial of patients aged 18 to 65 years, who had
tested positive for inﬂuenza A or B antigens, was performed. A total of 156 patients were enrolled as the
intention-to-treat population; these patients were assigned randomly to receive either Ergoferon or
oseltamivir (n = 78 in each group).
Results: The percentage of patients achieving a normal body temperature (37.08E) following 5 days of
treatment did not differ signiﬁcantly between the groups. The mean duration of fever in the Ergoferon
and oseltamivir groups was 2.1  1.5 days and 2.3  1.6 days, respectively (p = 0.01). The average time to
the resolution of inﬂuenza symptoms was approximately 3 days, with no signiﬁcant between-group
difference. Total quality of life scores were similar in the two groups following 5 days of drug administration.
The incidence of adverse events did not differ signiﬁcantly between the groups, nor were there any serious
adverse events.
Conclusions: Ergoferon and oseltamivir were equally effective and safe in adult outpatients with
seasonal inﬂuenza A or B virus infection.
Clinical trial registration: ClinicalTrials.gov identiﬁer NCT01804946
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Inﬂuenza is an infection affecting populations worldwide
caused by highly contagious, epidemically aggressive and
mutagenic viruses.1,2 More than 200 000 hospitalizations and
an average of 25 470 deaths occur in the USA each year due to
seasonal inﬂuenza.3,4 Resistance of inﬂuenza A viruses to
adamantanes increased globally in 2003 and has since become
universal for circulating inﬂuenza A(H1N1) and A(H3N2)* Corresponding author. Tel.: +79260902201.
E-mail address: AndrianovaEN@materiamedica.ru (E. Andrianova).
http://dx.doi.org/10.1016/j.ijid.2016.09.002
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).subtypes.5 The mainstay of inﬂuenza therapy therefore consists
primarily of the neuraminidase inhibitors oseltamivir and
zanamivir, which are licensed widely throughout the world.6
The pandemic caused by the 2009 inﬂuenza A(H1N1) virus, as
well as the increase in viral strains with resistance to neuramini-
dase inhibitors, has underscored the need for better treatment
options for hospitalized patients and outpatients.2 A drug with a
high efﬁcacy-to-safety ratio that is able to overcome the virus
resistance and that also has advantages from a pharmaco-
economic point of view could be attractive as a treatment option.
Ergoferon, a drug containing released-active forms of antibodies to
interferon gamma (IFN-g), CD4, and histamine, and whose efﬁcacy
and safety against inﬂuenza and acute respiratory viral infectionsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
V. Rafalsky et al. / International Journal of Infectious Diseases 51 (2016) 47–5548has been shown previously, could be considered one such drug.7–9
Released-active forms of antibodies are produced on the basis of a
novel technology (US Patent 8,535,664 B2, 2013) and share a
common feature – the ability to modify the initial substance (or
biological molecules which are structurally similar to the initial
substance) by changing its spatial structure, resulting in altera-
tions to its physical, chemical, and biological properties.10 The
efﬁcacy and safety of these drugs has been studied extensively and
has been proven in different experimental and clinical studies.11–18
The superiority of Ergoferon over placebo has been shown in
double-blind, placebo-controlled studies in adults and children
with acute upper respiratory viral infections and inﬂuenza.7–9 The
objective of this clinical trial was to compare the efﬁcacy and safety
of Ergoferon with oseltamivir in the treatment of seasonal
inﬂuenza in adults.
2. Methods
2.1. Study overview
This study was a multicenter, open-label, randomized con-
trolled trial performed in 12 medical institutions in Russia from
February 2011 to April 2014. This period succeeded the emergence
of the 2009 pandemic inﬂuenza A/H1N1 virus (pH1N1). Further-
more, the inﬂuenza morbidity in Russia was low during the study
period. The study was conducted in accordance with the principles
of the Declaration of Helsinki and Good Clinical Practice and was
approved by the institutional review boards and the national
research ethics committee. Signed informed consent was obtained
from all participants prior to enrollment. Due to the open design of
the trial, the interim analysis was performed in 2012 to compare
the efﬁcacy of the study treatments.19
Eligible patients were assessed by physicians on days 1, 3, and
7 in the outpatient departments of the study centers involved (see
Supplementary Material).
2.2. Patient selection
The study enrolled adults aged 18 to 65 years who presented to
hospital within 24 h of the onset of inﬂuenza symptoms and who
had an axillary temperature of 37.8 8C at enrollment plus one or
more ﬂu-related non-speciﬁc symptoms (headache, myalgia, joint
pain, sweats and/or chills, malaise, or fatigue) and one or more
respiratory symptoms (cough, sore throat, or nasal symptoms).
Infection with inﬂuenza A or B virus was conﬁrmed by rapid
antigen testing (QuickVue Inﬂuenza A+B test; Quidel Corporation,
San Diego, CA, USA).
Individuals were excluded from the study if they had an
exacerbation or decompensation of a chronic disease that would
affect their ability to participate in the clinical trial, chronic renal
insufﬁciency, vaccination against inﬂuenza prior to epidemic
season onset, medical history of polyvalent allergy, allergy/
intolerance to any of the components or medications used in
the treatment, suspected or known bacterial infection, a condition
requiring antibacterial therapy, or HIV disease. They were also
excluded if the were receiving systemic therapy with steroids or
other immunosuppressants, or had a history of alcohol or drug
abuse. Women were required to have a negative urine pregnancy
test before drug administration. Breastfeeding women were not
eligible for participation.
2.3. Patient assessment
Anterior nose and posterior pharyngeal throat swabs were
taken at baseline and assessed with the QuickVue Inﬂuenza A+B kit
for rapid diagnostic testing for inﬂuenza.The participants were monitored for a total of 7 days, with
hospital visits scheduled for days 1, 3, and 7. All visits included the
measurement of axillary temperature, a physical examination,
evaluation of inﬂuenza symptoms by the physician, and assess-
ment of the intake of concomitant therapies. The laboratory
analyses (hematology, blood chemistry, and urinalysis) were
performed on days 1 and 7. The severity of each inﬂuenza
symptom was scored by the physician on a symptom severity scale
(0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms;
3 = severe symptoms). Baseline and end-of-treatment quality of
life assessments were based on the ﬁrst ﬁve points of the European
Quality of Life Scale (EuroQoL, EQ5D); baseline and end-of-
treatment self-reported ‘health-related quality of life’ estimates
were obtained using a visual analogue health-rating scale (EQ5D,
point 6). The assessment of compliance with the study therapies
was done on the last visit (day 7).
Axillary temperature measurements were taken by the study
participants twice daily using a digital thermometer and recorded
on a diary card. The names and doses of concomitant medications
taken (other than the two drugs speciﬁcally assessed during the
study) were recorded in the patient diary.
Safety assessments included examiner-reported adverse events
(AEs) and self-reported AEs during the 5 days of treatment and the
following 30 days, as well as abnormal laboratory ﬁndings on day
7.
2.4. Treatment
The participants were assigned randomly to receive Ergoferon
(group 1) or oseltamivir (group 2). Randomization occurred at the
time of study entry by telephone contact with an automated
service (an interactive voice randomization system based on a
random number generator).
Ergoferon (OOO NPF ‘Materia Medica Holding’, Russia) was
administered according to the following regimen: on day 1, ﬁve
tablets were taken in the ﬁrst 2 h (one tablet every 30 min),
followed by three more tablets regularly spaced during the rest of
the day. From day 2 through day 5, one tablet was administered
three times daily. The efﬁcacy and safety of this speciﬁc drug
regimen has been assessed and proven in previous clinical trials.7,8
Each tablet of Ergoferon contains microcrystalline cellulose
(30 mg), magnesium stearate (3 mg), and lactose monohydrate
(267 mg) saturated with a mixture of afﬁnity puriﬁed rabbit
polyclonal antibodies to IFN-g, antibodies to histamine, and
antibodies to CD4 receptor, which had previously undergone a
process of gradual reduction of their initial concentration (2.0–
2.5 mg/ml) by 1024 times at least (mixture of dilutions 10012,
10030, and 10050). This technology conforms to the approach
described in the European Pharmacopoeia (general monographs
1038 and 2371) and allows the use of active pharmaceutical
ingredients – the released-active form of the above-mentioned
antibodies – based on a novel patented biotechnological platform
(US Patent 8,535,664 B2, 2013). The initial forms of the antibodies
were produced in accordance with the current EU requirements of
Good Manufacturing Practice for starting materials (EU Directive
2001/83/EC, as amended in Directive 2004/27/EC) by AB Biotech-
nology (Edinburgh, UK). The fact that properties of the active
pharmaceutical ingredients are based primarily on the technologi-
cal process of their preparation9 determines their crucial difference
from homeopathic therapy based on other common features (law
of similarity, individual hyperergic reactions, and speciﬁc meth-
odological principles of personalized indication).
Oseltamivir (Tamiﬂu; F. Hoffmann-La Roche, Ltd) was admin-
istered at a dose of 75 mg orally twice daily for 5 days; this is the
recommended dosing regimen for adults. Tamiﬂu was obtained
from a licensed wholesaler (SIA International Ltd).
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the study: antipyretic/non-steroidal anti-inﬂammatory drugs
(NSAIDs) (only for patients with a body temperature >38.5 8C),
decongestants, drugs for obstructive airway diseases, cough
suppressants, expectorants, mucolytics, and medications for the
treatment of underlying chronic conditions. The use of other
antivirals (except Ergoferon and oseltamivir), antihistamines,
antibacterials, and interferons was not permitted. The use of
NSAIDs and other medications for symptom relief was recorded by
the study researchers (physicians) on the case record form and by
the patient on a diary card.
2.5. Efﬁcacy endpoints
The percentage of patients with a body temperature 37.0 8C
following the 5-day treatment was used as the primary efﬁcacy
endpoint.
The secondary efﬁcacy endpoints were: (1) mean body
temperature; (2) ﬂu-related non-speciﬁc and respiratory symp-
tom severity score; (3) mean duration of fever; (4) time to
treatment-associated resolution of inﬂuenza symptoms; (5)
rates of antipyretic/NSAID use per patient during days 1 to 5 of
drug administration; (6) changes in patient quality of life (total
EQ5D scores) and self-reported ‘health-related quality of
life’ estimates between days 1 and 7; and (7) the percentage
of examiner-reported worsening of illness or complications
requiring antibacterial therapy during the three medical
visits.
2.6. Statistical methods
The study was based on a non-inferiority design. Sample size
calculations were based on assumed between-group equality of
patient proportions with body temperature 37.08E for each of
the ﬁve treatment days. The level of type I error was set at 5% and
the statistical power of the analysis at 80%. A one-tailed Z-test was
used. Assuming the most conservative hypothesis that the
proportions of patients with body temperature 37.08E in the
groups were distributed 50% versus 50%, the minimum sample
size required was estimated to be 78 patients in each group.
Overall, 156 patients, 78 in each group, were evaluated in this
study.
2.6.1. Efﬁcacy analysis
The intention-to-treat (ITT) and per-protocol (PP) analyses
were performed in accordance with the current guidelines
for evaluating drug efﬁcacy in a clinical non-inferiority
trial.20
Patient proportions were compared using frequency analysis
(Chi-square test or Fisher’s exact test) and Wald Z-statistics. For
the comparison of means, a modiﬁed paired Student t-test was
used with the calculation of the conﬁdence interval for
differences between sample means. For multiple comparisons,
the adaptive Holm procedure was used (the type I error (p-
value) used to describe the outcomes was adjusted using this
method).
2.6.2. Safety analysis
Treatment safety in both groups was assessed in all enrolled
and randomized patients who received at least one dose of
Ergoferon (n = 81) or oseltamivir (n = 80).
All recorded AEs, vital signs, clinical laboratory parameters, and
physical examination ﬁndings were listed, tabulated, and summa-
rized according to the treatment group. The documented AEs were
categorized by organ system, preferable terms, severity, and
treatment relatedness as determined by the physician.3. Results
3.1. Patient demographics and baseline characteristics
A total of 161 patients aged 18 to 60 years were enrolled in the
study, 81 in group 1 (Ergoferon) and 80 in group 2 (oseltamivir).
The date of the ﬁrst patient enrollment was February 28, 2011; the
date on which the last patient completed participation was April
21, 2014.
Five randomized patients (three in group 1 and two in group 2)
were excluded from the full analysis owing to a failure to satisfy
the major entry criteria (eligibility violations) (Figure 1). Eligibility
violations were the following: absence of the documented axillary
temperature of 37.8 8C at enrollment (n = 2 in group 1; n = 1 in
group 2) or any ﬂu-related symptoms (n = 1 in group 1; n = 1 in
group 2). The rest of the participants (n = 156) constituted the ITT
set analyzed. Treatment outcomes in this set (78 patients per
group) were considered for ITT analysis of efﬁcacy.
In addition, nine patients (three patients in group 1 and six
patients in group 2) had substantial protocol violations: absence of
the patient diary (n = 1 in group 1; n = 1 in group 2); temperature
gaps in the patient diary for 1 day (n = 1 in group 1; n = 2 in group
2); omissions in the case record form (n = 1 in group 1; n = 1 in
group 2). In group 2, two additional participants required the
administration of non-permitted medications (antibacterials) on
day 4. Hence, the PP analysis set included 147 patients: 75 in group
1 and 72 in group 2.
Basic demographic and clinical parameters (day 1) were
comparable between the treatment groups (Tables 1, 3–5). The
mean patient age was 34.7  12.1 years (ranging from 18 to
59 years); female patients made up 65% of the study population. The
majority of patients presented with typical inﬂuenza symptoms (e.g.
fever, headache, myalgia) and a predominance of non-speciﬁc over
respiratory symptoms. On day 1, the mean body temperature was
38.2  0.4 8C in group 1 and 38.3  0.4 8C in group 2 in the ITT set, and
38.3  0.48 C in both groups in the PP set. All patients in both groups
complained of moderate to severe headache, chills, fatigue, muscle
pain, and malaise. The mean severity score of ﬂu-related non-speciﬁc
symptoms on day 1 was 18.8  6.2 (19.0  6.7) in group 1 and
18.6  6.2 (18.6  6.3) in group 2 (hereinafter, ITT analysis data are
presented ﬁrst and PP analysis data are given in brackets). The
respiratory symptoms score did not differ signiﬁcantly between the
groups: 6.1  3.7 (6.1  3.7) in group 1 and 5.9  3.7 (5.9  3.6) in
group 2; these mostly represented moderate symptoms, such as nasal
congestion and sore throat.
More than 30% of patients had different underlying chronic
conditions that were not reasons for exclusion (see Supplemen-
tary Material, Table S1). Most of the patients in both groups
received additional permitted concomitant medications (see
Supplementary Material, Table S2). Neither the percentage of
patients with underlying chronic diseases nor the percentage of
patients receiving any additional permitted concomitant medica-
tion differed signiﬁcantly between the groups.
3.2. Primary efﬁcacy endpoints
The ITT analysis showed an effect of Ergoferon that was
comparable to that of oseltamivir for the 5 days of treatment: 19%
of patients in group 1 achieved a normal morning body
temperature (37.08E) as early as day 2 (versus 10% in group
2), 46% of patients in group 1 had a normalized body temperature
on day 3 (versus 42% in group 2), and 81% of patients in group 1 had
a normalized body temperature on day 5 (versus 71% in group 2)
(Table 2). At treatment completion (day 6), all patients in group
1 reported a normal morning body temperature (versus 92% in
group 2).
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Figure 1. Study design ﬂow diagram.
Table 1
Demographic characteristics of the study participantsa
No. Variable Group 1 Group 2 Statisticsb
1 Age (years), mean  SD (range)
Total set (81/80)c 34.5  11.6 34.9  12.6 t = 0.2; p = 0.84
(18–59) (18–58)
ITT (78/78)c 34.2  11.7 35.0  12.7 t = 0.41; p = 0.68
(18–59) (18–58)
PP (75/72)c 34.4  11.7 35.5  12.5 t = 0.58; p = 0.56
(18–59) (18–58)
2 Sex, n (%)
Total set (81/80)c
Male 32 (40) 25 (31) x2 = 1.2; p = 0.27
Female 49 (60) 55 (69)
ITT (78/78)c
Male 31 (40) 24 (31) x2 = 1.4; p = 0.24
Female 47 (60) 54 (69)
PP (75/72)c
Male 30 (40) 23 (32) x2 = 1.03; p = 0.31
Female 45 (60) 49 (68)
ITT, intention-to-treat analysis; PP, per-protocol analysis.
a Results are presented as the mean  standard deviation, or number (percentage).
b The Statistics column shows the results of the Student t-test (section 1) and
frequency analysis (section 2).
c The number of patients in group 1/number of patients in group 2.
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temperature (37.08E) in group 1 was 41% by day 3, 68% by day
4, and 85% by the end of day 5. Group 2 patients had nearly
identical values (42%, 69%, and 86%, respectively).
The PP analysis showed similar normalization rates for morning
and evening body temperatures in both groups (Table 2).
The ITT (PP) analysis demonstrated consistent results, which
suggests that the two study treatments have comparable
therapeutic effects (Table 2).
3.3. Secondary efﬁcacy endpoints
The ITT (CC) analysis of mean body temperature showed that
the increased baseline values fell to 37.0  0.5 8C by day 3 in both
groups and remained consistently below 37.0 8C over the subsequent
days of observation (Table 3). Statistical analysis showed mean values
of fever in group 1 falling within the acceptable ‘d’ limits established
for treatment outcomes in group 2 (ITT analysis: D8 = 0.01, 95%
conﬁdence interval (CI) <0.14, t =  2.5, p = 0.007; CC analysis:
D8 = 0.005, 95% CI <0.14, t = 2.4, p = 0.008), conﬁrming the
comparable efﬁcacy of the two drugs (Table 3).
The ITT analysis showed more than a two-fold reduction in ﬂu-
related non-speciﬁc symptom severity score in group 1 on the third
day, i.e., 9.2  5.0 (versus 7.7  4.4 in group 2) (Table 4). On the last
day of observation (day 7), the mean severity score in the Ergoferon
Table 2
Percentages of patients with a body temperature 37.08E during the study period
Treatment day ITT analysis PP analysis
Group 1 Group 2 Statisticsa Group 1 Group 2 Statisticsa
(n = 78) (n = 78) (n = 75) (n = 72)
1 Morning 0% 1% D = 1% (5% to 2%) 0% 1% D = 1% (5% to 3%)
Z = 13.7; p < 0.001 Z = 12.5; p < 0.001
Evening 4% 1% D = 3% (4% to 9%) 4% 1% D = 3% (4% to 9%)
Z = 8.4; p < 0.001 Z = 8.0; p < 0.001
2 Morning 19% 10% D = 9% (3% to 21%) 19% 10% D = 9% (4% to 21%)
Z = 4.9; p < 0.001 Z = 4.8; p < 0.001
Evening 14% 15% D = 1% (14% to 11%) 15% 15% D = 1% (14% to 12%)
Z = 3.1; p = 0.001 Z = 3.1; p = 0.001
3 Morning 46% 42% D = 4% (13% to 21%) 47% 43% D = 4% (14% to 21%)
Z = 2.8; p = 0.002 Z = 2.7; p = 0.003
Evening 41% 42% D = 1% (18% to 15%) 41% 43% D = 2% (19% to 16%)
Z = 2.2; p = 0.014 Z = 2.1; p = 0.019
4 Morning 81% 71% D = 10% (4% to 25%) 80% 75% D = 5% (10% to 20%)
Z = 4.2; p < 0.001 Z = 3.4; p < 0.001
Evening 68% 69% D = 1% (17% to 15%) 68% 72% D = 4% (20% to 12%)
Z = 2.3; p = 0.009 Z = 1.9; p = 0.028
5 Morning 95% 83% D = 12% (1% to 22%) 95% 83% D = 11% (0% to 23%)
Z = 6.2; p < 0.001 Z = 5.9; p < 0.001
Evening 85% 86% D = 1% (14% to 11%) 84% 88% D = 4% (16% to 9%)
Z = 3.1; p = 0.001 Z = 2.6; p = 0.004
6 Morning 100% 92% D = 8% (0% to 15%) 100% 92% D = 8% (1% to 16%)
Z = 8.8; p < 0.001 Z = 8.3; p < 0.001
Evening 94% 96% D = 3% (11% to 6%) 93% 96% D = 3% (11% to 6%)
Z = 4.6; p < 0.001 Z = 4.3; p < 0.001
ITT, intention-to-treat analysis; PP, per-protocol analysis.
a The Statistics column shows the results of the frequency analysis (non-inferiority Wald test) with 95% conﬁdence intervals in parentheses.
Table 3
Body temperature on days 1, 3, and 7a
Day ITT analysis PP analysis
Group 1 (n = 78) Group 2 (n = 78) Statisticsb Group 1 (n = 75) Group 2 (n = 72) Statisticsb
1 38.2  0.4 38.2  0.4 D8 = 0.0; 95% CI < 0.08
t = 3.6; p = 0.0002
38.3  0.4 38.3  0.4 D8 = 0.0; 95% CI < 0.08
t = 3.5; p = 0.0003
3 37.0  0.5 37.0  0.5 D8 = 0.01; 95% CI < 0.14
t = 2.5; p = 0.007
37.0  0.5 37.0  0.5 D8 = 0.005; 95% CI <0.14
t = 2.4; p = 0.008
7 36.5  0.2 36.6  0.3 - 36.5  0.2 36.6  0.3 -
ITT, intention-to-treat analysis; PP, per-protocol analysis; CI, conﬁdence interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of the Student t-test modiﬁed for comparability (non-inferiority) testing. D8 is the mean difference between group 1 (Ergoferon)
and group 2 (oseltamivir). The p-value stands for type I error.
Table 4
Flu-related non-speciﬁc symptom severity scores on days 1, 3, and 7a
Day ITT analysis PP analysis
Group 1 (n = 78) Group 2 (n = 78) Statisticsb Group 1 (n = 75) Group 2 (n = 72) Statisticsb
1 18.8  6.6 18.6  6.2 D = 0.2; 95% CI <1.9
t = 2.7; p = 0.003
19.0  6.7 18.6  6.3 D = 0.4; 95% CI <2.1
t = 2.5; p = 0.007
3 9.2  5.0 7.7  4.4 D = 1.5; 95% CI <2.8
t = 2.0; p = 0.025
9.2  5.1 7.8  4.3 D = 0.45;95% CI <2.8
t = 2.0; p = 0.02
7 2.4  2.9 2.0  2.5 D = 0.4; 95% CI <1.1
t = 5.9; p < 0.0001
2.3  2.7 1.9  2.3 D = 0.39; 95% CI <1.1
t = 6.3; p < 0.0001
ITT, intention-to-treat analysis; PP, per-protocol analysis; CI, conﬁdence interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of the Student t-test modiﬁed for comparability (non-inferiority) testing. D is the mean difference between group 1 (Ergoferon)
and group 2 (oseltamivir). The p-value stands for type I error.
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PP analysis yielded almost identical values (Table 4).
The respiratory symptom scores were signiﬁcantly reduced on
treatment day 3 and this reduction was similar in the two groups
(for both ITT and PP data). At the completion of treatment, some
patients in both groups reported ‘residual’ catarrhal symptoms, as
shown by the mean severity score of over 1.0 (Table 5).The mean duration of fever was 2.1  1.5 (2.1  1.4) days in
group 1 versus 2.3  1.6 (2.3  1.6) days in group 2. This variable was
similar in the two groups (p = 0.01 (p = 0.002)) (Table 6).
The analysis of time to treatment-associated resolution of
inﬂuenza symptoms showed that the ﬂu-related non-speciﬁc
symptoms had resolved at 2.7  2.2 days in group 1 and at
2.4  2.1 days in group 2, whereas the improvement in respiratory
Table 5
Respiratory symptom severity scores on days 1, 3, and 7a
Day ITT analysis PP analysis
Group 1 (n = 78) Group 2 (n = 78) Statisticsb Group 1 (n = 75) Group 2 (n = 72) Statisticsb
1 6.1  3.7 5.9  3.7 D = 0.2; 95% CI <1.2
t = 2.1; p = 0.02
6.1  3.7 5.9  3.6 D = 0.2; 95% CI <1.2
t = 2.1; p = 0.02
3 4.3  2.4 3.9  2.7 D = 0.4; 95% CI <1.1
t = 2.7; p = 0.004
4.3  2.4 4.0  2.7 D = 0.3; 95% CI <1.0
t = 2.8; p = 0.003
7 1.3  1.5 1.4  1.9 D = 0.1; 95% CI <0.4
t = 5.8; p < 0.0001
1.3  1.5 1.4  1.8 D = 0.1; 95% CI <0.4
t = 5.9; p < 0.0001
ITT, intention-to-treat analysis; PP, per-protocol analysis; CI, conﬁdence interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of the Student t-test modiﬁed for comparability (non-inferiority) testing. D is the mean difference between group 1 (Ergoferon)
and group 2 (oseltamivir). The p-value stands for type I error.
Table 6
Duration of fever and time to treatment-associated resolution of inﬂuenza symptomsa
Symptom Duration of symptoms, days
ITT analysis PP analysis
Group 1 (n = 78) Group 2 (n = 78) Statisticsb Group 1 (n = 75) Group 2 (n = 72) Statisticsb
Fever 2.1  1.5 2.3  1.6 D = 0.13; 95% CI <0.28
t = 2.4; p = 0.01
2.1  1.4 2.3  1.6 D = 0.24; 95% CI <0.17
t = 2.8; p = 0.002
Flu-related non-speciﬁc symptoms 2.7  2.2 2.4  2.1 D = 0.29; 95% CI <0.47
t = 1.7; p = 0.04
2.6  2.2 2.4  2.1 D = 0.26; 95% CI <0.44
t = 1.96; p = 0.025
Respiratory symptoms 2.8  2.5 2.6  2.6 D = 0.15; 95% CI <0.45
t = 2.1; p = 0.02
2.7  2.5 2.6  2.6 D = 0.09; 95% CI <0.40
t = 2.3; p = 0.01
All inﬂuenza symptoms 2.7  2.3 2.5  2.2 D = 0.22; 95% CI <0.37
t = 3.0; p = 0.001
2.6  2.3 2.5  2.2 D = 0.17; 95% CI <0.33
t = 3.4; p = 0.0003
ITT, intention-to-treat analysis; PP, per-protocol analysis; CI, conﬁdence interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of the Student t-test modiﬁed for comparability (non-inferiority) testing. D is the mean difference between group 1 (Ergoferon)
and group 2 (oseltamivir). The t-test was calculated for differences between means to determine their signiﬁcance as compared to the pre-deﬁned delta (margin). The p-value
stands for type I error.
Table 7
Number of antipyretic and NSAIDs takena
Day ITT analysis CC analysis
Group 1
(n = 78)
Group 2
(n = 78)
Statisticsb Group 1
(n = 75)
Group 2
(n = 72)
Statisticsb
1 0.65  0.48 0.69  0.46 D = 0.04; 95% CI <0.09
t = 3.16; p = 0.001
0.65  0.48 0.72  0.45 D = 0.07; 95% CI <0.06
t = 3.5; p = 0.0003
2 0.40  0.49 0.49  0.50 D = 0.09; 95% CI <0.04
t = 3.63; p = 0.0002
0.40  0.49 0.49  0.50 D = 0.09; 95% CI <0.05
t = 3.48; p = 0.0003
3 0.19  0.40 0.15  0.36 D = 0.04; 95% CI <0.14
t = 2.65; p = 0.0044
0.19  0.39 0.15  0.36 D = 0.03; 95% CI <0.14
t = 2.66; p = 0.0043
4 0.01  0.11 0.04  0.19 D = 0.03; 95% CI <0.02
t = 8.89; p < 0.0001
0.01  0.12 0.04  0.20 D = 0.03; 95% CI <0.02
t = 8.48; p < 0.0001
5 0.01  0.11 0.03  0.16 D = 0.01; 95% CI <0.02
t = 9.63; p < 0.0001
0.01  0.12 0.03  0.17 D = 0.01; 95% CI <0.02
t = 9.14; p < 0.0001
NSAID, non-steroidal anti-inﬂammatory drug; ITT, intention-to-treat analysis; PP, per-protocol analysis; CI, conﬁdence interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of the Student t-test modiﬁed for comparability (non-inferiority) testing. D is the mean difference between group 1 (Ergoferon)
and group 2 (oseltamivir). The p-value stands for type I error.
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2.6  2.6 days, respectively (Table 6). The mean duration of all
inﬂuenza symptoms was 2.7  2.3 and 2.5  2.2 days in group 1 and
group 2, respectively. The statistical analysis of ITT and CC sets
indicated consistent comparability of treatment outcomes in the two
groups (Table 6). On average, most inﬂuenza symptoms had resolved
after approximately 3 days of treatment, without signiﬁcant
differences in either ITT or CC data between the groups (Table 6).
The mean rate of antipyretic/NSAID intake on day 1 as
calculated on a per-patient basis was 0.65  0.48 (0.65  0.48) in
group 1 and 0.69  0.46 (0.72  0.45) in group 2 (Table 7). By day 3,
this variable was reduced to 0.19  0.40 (0.19  0.39) in group 1 and0.15  0.36 (0.15  0.36) in group 2. The statistical analysis
demonstrated consistent comparability of endpoint values in the
treatment groups (p < 0.005 (p < 0.005)).
By day 7, the mean EQ5D score in group 1 was 5.4  0.8 (versus a
baseline score of 9.4  1.9), indicating a signiﬁcant improvement in
patient health (D1–7 = 4.0), and similar results were obtained in
group 2 (5.5  0.9 and 9.2  2.3, respectively; D1–7 = 3.7) (Table 8).
Based on patient self-reported health estimates on the health-
rating scale, the mean total score in group 1 was increased more
than two-fold, from 42.1  18.4 at baseline to 87.7  10.6
(D1–7 = 45.6), and an increase from 46.7  15.1 to 87.8  11.4
(D1–7 = 41.1) was observed in group 2. These data were consistent
Table 8
Total EQ5D scores and self-reported health estimatesa
Day ITT analysis PP analysis
Group 1
(n = 78)
Group 2
(n = 78)
Statisticsb Group 1
(n = 75)
Group 2
(n = 72)
Statisticsb
EQ5D Questionnaire, score
1 9.4  1.9 9.2  2.3 9.6  1.9 9.4  2.2
7 5.4  0.8 5.5  0.9 5.3  0.9 5.4  0.8
D1–7 4.1  1.8 3.7  2.3 D = 0.4; 95% CI <0.2 4.2  1.8 3.9  2.2 D = 0.3; 95% CI <0.3
t = 3.4; p = 0.0005 t = 3.2; p = 0.0009
Health rating scale, score
1 42.1  18.4 46.7  15.1 41.6  18.2 46.2  15.4
7 87.7  10.6 87.8  11.4 87.7  10.7 88.0  10.6
D1–7 45.5  20.3 41.2  16.4 D = 4.5; 95% CI >0.5 46.1  20.0 41.8  15.7 D = 4.2; 95% CI >0.7
t = 4.3; p < 0.0001 t = 4.3; p < 0.0001
EQ5D, European Quality of Life Questionnaire; ITT, intention-to-treat analysis; PP, per-protocol analysis; D1–7, within-group mean difference on days 1 and 7; CI, conﬁdence
interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of the Student t-test modiﬁed for comparability (non-inferiority) testing. D is the between-group difference in D1–7 values. The p-
value stands for type I error.
Table 9
Number of patients with complications requiring antibacterial therapy
ITT analysis CC analysis
Group 1 (n = 78) Group 2 (n = 78) Statisticsa Group 1(n = 75) Group 2 (n = 72) Statisticsa
0 2 (3%) D = 3% (7% to 2%)
Z = 11.9; p < 0.0001
0 1 (1%) D = 1% (5% to 3%)
Z = 14.5; p < 0.0001
ITT, intention-to-treat analysis; PP, per-protocol analysis.
a The Statistics column shows the results of the frequency analysis for comparability testing (non-inferiority Wald test) with 95% conﬁdence intervals in parentheses.
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EQ5D score and in patient self-reported health estimates conﬁrmed
signiﬁcant between-group comparability (Table 8).
In group 1, neither worsening of illness nor complications
requiring antibacterial therapy or hospitalization were recorded,
whereas two patients in group 2 developed complications (one
case of community-acquired pneumonia affecting the lower lobe
of the left lung on day 4, and one case of acute maxillary sinusitis
on day 5) and were prescribed antibiotic therapy (Table 9).
3.4. Safety analysis
A total of 25 AEs were reported for 11 subjects in group 1, and
24 AEs were reported for 15 subjects in group 2. No serious AEs
were recorded. The incidence of AEs did not differ between the
groups (Table 10). The total list of AEs in the safety population is
presented in the Supplementary Material (Table S3).
In group 1, all AEs were mild with an uncertain (n = 22) or
possible (n = 3) relationship to the study treatment as determined
by the physician. Most patients who experienced AEs (n = 10) had
some abnormal laboratory ﬁndings, as revealed by the examina-
tion on day 7. The total number of abnormal laboratory ﬁndings in
group 1 was 23, and all of them were mild.Table 10
Number of patients with AEs and number of AEs per patient
Variable Group 1
(n = 81)
Number of patients with AEs, n (%) 11 (14%) 
Number of AEs in group 25 
Number of AEs per patient 0.30  1.07 
AE, adverse event; NA, not applicable; CI, conﬁdence interval.
a For the number of patients with AEs, the Statistics column shows the results of th
parentheses. For the number of AEs per patient, the Statistics column shows the resultIn group 2, a total of ﬁve moderate and 19 mild AE cases were
reported, including acute pneumonia (n = 1), acute maxillary
sinusitis (n = 1), difﬁculty breathing (n = 1), depressed mood
disorder (n = 1), and nausea (n = 2). The total number of abnormal
laboratory ﬁndings on day 7 in group 2 was 18. Five AEs were
unrelated to the treatment; 19 AEs had an uncertain (n = 17) or
possible (n = 2) relationship to the treatment.
Neither Ergoferon nor oseltamivir had negative effects on vital
functions (see Supplementary Material, Table S4).
There was no evidence of any drug–drug interaction with
medications administered concomitantly with Ergoferon or
oseltamivir (see Supplementary Material, Table S2).
Patients in both groups had approximately 100% compliance
with the therapies (Table 11). Patients in group 1 had good
tolerance of Ergoferon and all recovered at the end of treatment. In
group 2, two patients had complications requiring antibacterial
treatment.
4. Discussion
Oseltamivir has been evaluated extensively in randomized
controlled trials7,8,20 and was chosen as the comparator to
demonstrate the non-inferiority of Ergoferon in patients withGroup 1
(n = 80)
Statisticsa
15 (19%) D = 5% (18% to 7%)
Z = 4.1; p < 0.0001
24 NA
0.28  0.73 D = 0.02; 95% CI<0.26
t = 0.2; p = 0.405
e frequency analysis (non-inferiority Wald test) with 95% conﬁdence intervals in
s of the Student t-test modiﬁed for comparability (non-inferiority) testing.
Table 11
Rates of compliance with the study therapiesa
Variable ITT analysis PP analysis
Group 1 (n = 78) Group 2 (n = 78) Statisticsb Group 1 (n = 75) Group 2 (n = 72) Statisticsb
Compliance, % 101  4 100  0 D = 1; 95% CI >2
t = 18.1; p < 0.0001
101  4 100  0 D = 1; 95% CI >2
t = 19.0; p < 0.0001
ITT, intention-to-treat analysis; PP, per-protocol analysis; CI, conﬁdence interval.
a Results are presented as the mean  standard deviation.
b The Statistics column shows the results of Student t-test modiﬁed for comparability (non-inferiority) testing. D is the mean difference between group 1 (Ergoferon) and
group 2 (oseltamivir). The p-value stands for type I error.
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in spite of the fact that the efﬁcacy of oseltamivir has been
questioned (Cochrane systematic review, 2014),21 the World
Health Organization (WHO) recommends it as the ﬁrst-line
inﬂuenza treatment (http://www.who.int/mediacentre/
factsheets/fs211/en/) and the drug is on the WHO List of Essential
Medicines.22
The ﬁnal results of this study support those of the previously
published interim analysis in which only about a third of the ﬁnal
number of patients was enrolled.19 The therapeutic effect of
Ergoferon is comparable to that of oseltamivir. The percentage of
patients with absence of fever, which is known to correlate with
virus clearance and the antiviral efﬁcacy of the therapy,23 was
evaluated as the primary efﬁcacy endpoint. Ergoferon was shown
to have the same effect as oseltamivir on the duration of fever: over
two-thirds of patients reported a body temperature of 37.0 8C by
the end of day 4. At treatment completion, the percentages of
patients with normal morning and evening body temperatures
were similar in the two groups. The mean duration of the febrile
period in the Ergoferon group was approximately 2 days without
signiﬁcant difference from the oseltamivir group, and this efﬁcacy
is similar to the previously published data.
Ergoferon intake halved the severity of the inﬂuenza symptoms
(headache, muscular pain, and joint pain) by day 3. On average, the
mean duration of inﬂuenza symptoms was about 2 days in the
Ergoferon group and was comparable to that in the oseltamivir
group. A meta-analysis published in The Lancet demonstrated a
median time to inﬂuenza symptom alleviation of 97.5 h (or
4.1 days) for ambulant patients receiving oseltamivir.24 In
addition, the statistical analysis indicated consistent comparability
of the rates of antipyretic use in both groups.
Furthermore, there were no cases of worsening illness or
complications among the study patients. Improved quality of life
estimates reported by the patients taking Ergoferon were
consistent with the signiﬁcant improvement in total EQ5D scores
and patient health self-assessments from baseline.
The pharmacological activity of Ergoferon is ensured by the
combined action of its components on the antiviral immune
response and virus-induced respiratory tract inﬂammation. Each
component of Ergoferon exerts a modulating effect on its
respective target, as is a common feature of released-active forms
of antibodies.10 The main component of the drug – technologically
treated forms of antibodies to IFN-g – increases the expression of
IFN-g (a key cytokine participating in the antiviral immune
response), IFN-a/b, and associated interleukins (IL-2, IL-4, IL-10).
It also improves the ligand–receptor interaction of IFN-g with its
receptor, normalizes the concentration and functional activity of
natural antibodies to IFN-g, induces antigen expression of major
histocompatibility complex (MHCI and MHCII) and Fc-receptors,
stimulates natural killer (NK) cell and monocyte functional
activity, and activates a mixed Th1 and Th2 immune response.16,25
Other components of the drug, technologically treated forms of
antibodies to histamine and to CD4, have effects on histamine
receptor26 and CD4 receptor,27 respectively.This study has some limitations that could be considered as
sources of bias: the open-label trial design, the absence of a placebo
group and an untreated group, the long enrollment period (such
that the outcome of many patients was known before others had
been enrolled), a number of measurements of key variables
performed, and the use of patient self-report.
In conclusion, Ergoferon and oseltamivir were equally effective
and safe in the treatment of adults with seasonal inﬂuenza. It is
hoped that Ergoferon will become useful in the treatment of
patients infected with virus that has developed resistance to
current inﬂuenza drugs. The cost of a 5-day treatment with
Ergoferon is signiﬁcantly lower than that of a 5-day treatment with
Tamiﬂu.
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